Fig. 8
From: Extracellular vesicles: a rising star for therapeutics and drug delivery
Reprinted with permission from Ref [188]
a In vivo fluorescence imaging showing the whole-body biodistribution and 4T1 tumor-specific accumulation of ICG-labeled Sc-uPA and uPA nano-cocktail formulations administered via tail vein injection on days 0, 6, and 12, and imaged on days 2, 7, and 15 using a Lago (Spectral Imaging system) in vivo imaging system. Photoacoustic imaging of 4T1 tumors to examine the accumulation of ICG-labeled eEV-uPA-PLGA-AntimiRNA on day 16. b Survival curves of 4T1 tumor-bearing mice treated with different formulations (Saline; Low-dose DOX alone; Sc-uPA nano-cocktail; and uPA nano-cocktail). Ten animals from each group were used for assessing the survival rate (n = 10). c 4T1 tumor growth kinetics following different treatments. d Ex vivo images of tumors excised 1 month after treatment. e Body weight of mice receiving different treatments. f Number of metastatic nodules in the lungs following different treatments. g Histologic assessment of mouse lungs and tumors using H&E staining.